NCT03058965

Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain

Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Probable Alzheimer's Disease or Progressive Supranuclear Palsy Compared With Healthy Volunteers

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Molecular NeuroImaging · Academic / Other
• Sex: All
• Age: 50 Years – 90 Years
• Healthy volunteers: Accepted

Summary

The overall goal of this imaging trial is to evaluate \[18F\]MNI-958, a tau targeted PET radioligand, in individuals with Alzheimer's disease (AD), Progressive Supranuclear Palsy (PSP), and healthy volunteers (HV).

Conditions

• Alzheimer Disease
• Healthy Volunteers
• Progressive Supranuclear Palsy

Interventions

Type	Name	Description
DRUG	[18F]MNI-958	Subjects will undergo PET imaging using \[18F\]MNI-958, a PET radioligand for imaging tau.
DRUG	[18F]Florbetapir	Subjects with Alzheimer's disease will receive a \[18F\]florbetapir scan to compare distribution of tau in the brain compared to that of \[18F\]MNI-958.
DRUG	DaTscan	DaTscan SPECT imaging will be completed in those PSP subjects who have not previously had DATScan imaging as part of the screening procedures.

Timeline

• Start date: 2016-11-29
• Primary completion: 2018-05-11
• Completion: 2018-05-11
• First posted: 2017-02-23
• Last updated: 2019-03-25

Locations

1 site across 1 country: United States